22. Mai 2024 – SixPeaks Bio AG today emerged from stealth mode with a pipeline of therapies for healthy weight loss, including a potentially best-in-class dual-specific antibody targeting activin type IIA and B receptors. The company has secured USD 30 million in Series A financing led by founding investor Versant Ventures and a strategic collaboration with AstraZeneca that will provide additional, non-dilutive financing of up to USD 80 million over the next two years. AstraZeneca also has certain exclusive rights to acquire SixPeaks during this period. SixPeaks was founded in 2022 at Versant's Ridgeline Discovery Engine in the Basel Technology Park with the goal of developing improved therapies for healthy weight loss.

Walder Wyss advised SixPeaks Bio AG on all Swiss law aspects of the transaction. The Walder Wyss team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital), Michelle Bruni (Managing Associate, Tax), Lucas Maurer (Associate, Corporate/M&A and Venture Capital, Commercial Contracts) and Simon Olstein (Associate, Corporate/M&A and Venture Capital, Commercial Contracts).